Challenges and Opportunities in Developing Neurologic Therapies | Page 7

Kaitin KI. Deconstructing the drug development process: the new face of
innovation. Clin Pharmacol Ther. 2010;87(3):356-61.
No authors given. NeuroNEXT: accelerating drug development in neurology.
Lancet Neurol. 2012;11(2):119.
Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders:
strategies for balancing risk and reducing attrition. Nat Rev Drug Discov.
2007;6(7):521-32.
Preskorn S. CNS Drug Development: Part III: Future Directions. J Psychiatric
Pract. 2011;17(1):49-52.
Pritchard JF. Risk in CNS drug discovery: focus on treatment of Alzheimer’s
disease. BMC Neuroscience. 2008;9(Suppl 3):S1.
Richards D. Drug development and regulation. Medicine. 2008;36:369-76.
Shineman DW, Fillit HM. Meeting the unique challenges of drug discovery for
neurodegenerative diseases. BMC Neurol. 2009;9(Suppl 1):11.
Steinmetz KL, Spack EG. The basics of preclinical drug development for
neurodegenerative disease indications. BMC Neurol. 2009;9(Suppl 1):S2.
World Health Organization. Neurological disorders: Public health challenges.
2006. Available at:
http://www.who.int/mental_health/neurology/neurodiso/en/. Accessed on 31
January 2012.